Your browser doesn't support javascript.
loading
Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
Rizzoli, R; Benhamou, C-L; Halse, J; Miller, P D; Reid, I R; Rodríguez Portales, J A; DaSilva, C; Kroon, R; Verbruggen, N; Leung, A T; Gurner, D.
Affiliation
  • Rizzoli R; Division of Bone Diseases, Geneva University Hospitals, CH-1211, Geneva 14, Switzerland. Rene.Rizzoli@unige.ch.
  • Benhamou CL; Hopital d'Orléans la Source, Orléans, France.
  • Halse J; Osteoporoseklinikken, Oslo, Norway.
  • Miller PD; Colorado Center for Bone Research, University of Colorado Health Sciences Center, Lakewood, CO, USA.
  • Reid IR; University of Auckland, Auckland, New Zealand.
  • Rodríguez Portales JA; Pontificia Universidad Católica de Chile, Santiago, Chile.
  • DaSilva C; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Kroon R; Formerly MSD, Oss, The Netherlands.
  • Verbruggen N; MSD Europe Inc., Brussels, Belgium.
  • Leung AT; Formerly Merck & Co., Inc., Kenilworth, NJ, USA.
  • Gurner D; Merck & Co., Inc., Kenilworth, NJ, USA.
Osteoporos Int ; 27(6): 2099-107, 2016 06.
Article in En | MEDLINE | ID: mdl-26879200
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Biphenyl Compounds / Bone Density / Osteoporosis, Postmenopausal / Bone Density Conservation Agents Type of study: Clinical_trials Language: En Journal: Osteoporos Int Year: 2016 Type: Article Affiliation country: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Biphenyl Compounds / Bone Density / Osteoporosis, Postmenopausal / Bone Density Conservation Agents Type of study: Clinical_trials Language: En Journal: Osteoporos Int Year: 2016 Type: Article Affiliation country: Switzerland